Positive Phase 1b results for Heptares’ HTL9936
10 February 2016 | By Victoria White
HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...